▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #159 by analyst upside · 2026-11-13
RNTX
Rein Therapeutics Inc.
Healthcare · Market Cap $48M · P/E 0x
ANALYST PRICE TARGET
+971.4%
implied upside to consensus target
Current Price $0.56
Consensus Target $6.0
Bull Target $8.0
Bear Target $4.0
Analysts Covering 2
ANALYST CONSENSUS - STRONG BUY
Strong Buy
1
Buy
1
Hold
0
Sell
0
52-Week Low $0.54
52-Week High $2.1
YTD Return -55.2%
FUNDAMENTALS
Market Cap $48M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.68
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.54
52-Week High $2.1
Current Price $0.56
Bear Target $4.0
Bull Target $8.0
● Now $0.56 ● Target $6.0
TRADING DATA
Avg Volume 426K
YTD Return -55.2%
Analyst Count 2
Consensus Strong Buy
Upside to Target +971.4%
Last Updated 2026-11-13

ANALYST SUMMARY

Rein Therapeutics Inc. (RNTX) is currently trading at $0.56 with a Wall Street consensus price target of $6.0, implying potential upside of 971.4% over the next 12 months. 2 analysts currently cover RNTX, with a consensus rating of Strong Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $8.0, while the most cautious has a target of $4.0.

RNTX operates in the Healthcare sector with a market capitalisation of $48M. The stock is down 55.2% year-to-date and is currently trading near the lower end of its 52-week range of $0.54 – $2.1.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for RNTX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-08-18 31% win rate (48 calls)
Maxim Group ● Initiated
Buy 2026-07-20 28% win rate (40 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-06-01 31% win rate (48 calls)
Brookline Capital ↓ Downgrade
Buy → Hold 2026-01-21 20% win rate (5 calls)
HC Wainwright & Co. ● Initiated
Buy 2025-09-22 31% win rate (48 calls)
Brookline Capital ↓ Downgrade
Buy → Hold 2025-08-19 20% win rate (5 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
35
out of 100
Coverage depth
8/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →